 JENA, Germany, Sept. 09, 2021 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually. The presentation will be available on demand starting at 7:00 AM EDT 1:00 PM CET on Monday, September 13, 2021. 